Suppr超能文献

起源于内翻性鼻窦乳头状瘤的鼻窦鳞状细胞癌中的高频可靶向表皮生长因子受体突变

High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.

作者信息

Udager Aaron M, Rolland Delphine C M, McHugh Jonathan B, Betz Bryan L, Murga-Zamalloa Carlos, Carey Thomas E, Marentette Lawrence J, Hermsen Mario A, DuRoss Kathleen E, Lim Megan S, Elenitoba-Johnson Kojo S J, Brown Noah A

机构信息

Department of Pathology, University of Michigan Health System, Ann Arbor, MI.

Department of Otolaryngology/Head and Neck Surgery, University of Michigan Health System, Ann Arbor, MI.

出版信息

Cancer Res. 2015 Jul 1;75(13):2600-2606. doi: 10.1158/0008-5472.CAN-15-0340. Epub 2015 Apr 30.

Abstract

Inverted sinonasal papilloma (ISP) is a locally aggressive neoplasm associated with sinonasal squamous cell carcinoma (SNSCC) in 10% to 25% of cases. To date, no recurrent mutations have been identified in ISP or SNSCC. Using targeted next-generation sequencing and Sanger sequencing, we identified activating EGFR mutations in 88% of ISP and 77% of ISP-associated SNSCC. Identical EGFR genotypes were found in matched pairs of ISP and associated SNSCC, providing the first genetic evidence of a biologic link between these tumors. EGFR mutations were not identified in exophytic or oncocytic papillomas or non-ISP-associated SNSCC, suggesting that the ISP/SNSCC spectrum is biologically distinct among sinonasal squamous tumors. Patients with ISP harboring EGFR mutations also exhibited an increased progression-free survival compared with those with wild-type EGFR. Finally, treatment of ISP-associated carcinoma cells with irreversible EGFR inhibitors resulted in inactivation of EGFR signaling and growth inhibition. These findings implicate a prominent role for activating EGFR mutations in the pathogenesis of ISP and associated SNSCC and rationalize consideration of irreversible EGFR inhibitors in the therapy of these tumors.

摘要

内翻性鼻窦乳头状瘤(ISP)是一种具有局部侵袭性的肿瘤,在10%至25%的病例中与鼻窦鳞状细胞癌(SNSCC)相关。迄今为止,尚未在ISP或SNSCC中发现复发性突变。通过靶向二代测序和桑格测序,我们在88%的ISP和77%的与ISP相关的SNSCC中发现了激活型表皮生长因子受体(EGFR)突变。在配对的ISP和相关SNSCC中发现了相同的EGFR基因型,为这些肿瘤之间的生物学联系提供了首个遗传学证据。在外生性或嗜酸性细胞瘤或与ISP无关的SNSCC中未发现EGFR突变,这表明在鼻窦鳞状肿瘤中,ISP/SNSCC谱系在生物学上是不同的。与野生型EGFR患者相比,携带EGFR突变的ISP患者的无进展生存期也有所延长。最后,用不可逆EGFR抑制剂治疗与ISP相关的癌细胞导致EGFR信号失活和生长抑制。这些发现表明激活型EGFR突变在ISP和相关SNSCC的发病机制中起重要作用,并为在这些肿瘤的治疗中考虑使用不可逆EGFR抑制剂提供了理论依据。

相似文献

1
High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.
Cancer Res. 2015 Jul 1;75(13):2600-2606. doi: 10.1158/0008-5472.CAN-15-0340. Epub 2015 Apr 30.
4
Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma.
Am J Surg Pathol. 2021 Jan;45(1):108-118. doi: 10.1097/PAS.0000000000001566.
5
6
EGFR and BRAF mutations in inverted sinonasal papilloma - a more complex landscape?
Virchows Arch. 2021 May;478(5):915-924. doi: 10.1007/s00428-020-02945-y. Epub 2020 Oct 13.
7
Sinonasal squamous cell carcinoma and EGFR mutations: a molecular footprint of a benign lesion.
Histopathology. 2018 Dec;73(6):953-962. doi: 10.1111/his.13732. Epub 2018 Oct 23.
10
Treatment outcome and pattern of recurrence of sinonasal squamous cell carcinoma with EGFR-mutation and human papillomavirus.
J Craniomaxillofac Surg. 2021 Jun;49(6):494-500. doi: 10.1016/j.jcms.2021.02.016. Epub 2021 Feb 22.

引用本文的文献

1
EGFR mutations in sinonasal squamous neoplasms: Novel hotspot for exon 20 insertions.
Virchows Arch. 2025 Mar 13. doi: 10.1007/s00428-025-04070-0.
2
Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
ESMO Open. 2025 Feb;10(2):104121. doi: 10.1016/j.esmoop.2024.104121. Epub 2025 Feb 6.
4
Identification and validation of Novel Estrogen Biosynthesis Biomarkers in Sinonasal Inverted Papilloma.
Int J Med Sci. 2025 Jan 1;22(1):158-169. doi: 10.7150/ijms.101753. eCollection 2025.
7
[Inverted papilloma of the nose and paranasal sinuses : Diagnosis, treatment, and malignant transformation].
HNO. 2024 Apr;72(4):257-264. doi: 10.1007/s00106-023-01406-7. Epub 2024 Jan 12.
8
Global research on sinonasal inverted papilloma over the past two decades: a bibliometric analysis.
Acta Otorhinolaryngol Ital. 2024 Apr;44(2):83-90. doi: 10.14639/0392-100X-N2522. Epub 2023 Dec 29.
9
An in vitro model and the underlying pathways of sinonasal inverted papilloma development.
Sci Rep. 2023 Oct 27;13(1):18456. doi: 10.1038/s41598-023-45585-3.
10
Differentiated Papillary NUT Carcinoma: An Unexpected, Deceptively Bland Presentation of a Sinonasal Carcinoma.
Head Neck Pathol. 2023 Sep;17(3):803-807. doi: 10.1007/s12105-023-01554-w. Epub 2023 Apr 28.

本文引用的文献

2
Low prevalence of K-RAS, EGF-R and BRAF mutations in sinonasal adenocarcinomas. Implications for anti-EGFR treatments.
Pathol Oncol Res. 2014 Jul;20(3):571-9. doi: 10.1007/s12253-013-9730-1. Epub 2013 Dec 15.
3
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Mol Cancer Ther. 2013 Feb;12(2):220-9. doi: 10.1158/1535-7163.MCT-12-0620. Epub 2013 Jan 31.
4
EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.
Cell Oncol (Dordr). 2012 Dec;35(6):443-50. doi: 10.1007/s13402-012-0103-7. Epub 2012 Oct 11.
5
In inverted papillomas HPV more likely represents incidental colonization than an etiological factor.
Virchows Arch. 2011 Nov;459(5):529-38. doi: 10.1007/s00428-011-1139-1. Epub 2011 Sep 9.
6
The mutational landscape of head and neck squamous cell carcinoma.
Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.
7
Sinonasal inverted papilloma: narrative review.
J Laryngol Otol. 2010 Jul;124(7):705-15. doi: 10.1017/S0022215110000599. Epub 2010 Apr 14.
10
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Oncogene. 2008 Aug 7;27(34):4702-11. doi: 10.1038/onc.2008.109. Epub 2008 Apr 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验